HDAC6 and cancer: HDAC6 has recently emerged as a major target in cancer immunotherapy because of its role in regulating the transcriptional activity of STAT3 and expression of a range of immune signalling proteins, most notably, cell death protein-1 (PD-1) and programmed death ligand 1 (PD-L1).